{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:24:09Z","timestamp":1792347849269,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006396","name":"Qazvin University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11064-018-2522-y","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T09:29:20Z","timestamp":1522747760000},"page":"1086-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model"],"prefix":"10.1007","volume":"43","author":[{"given":"Mohammad Reza","family":"Sarukhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-8758","authenticated-orcid":false,"given":"Hashem","family":"Haghdoost-Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Khandan-Chelarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"issue":"9680","key":"2522_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373(9680):2055\u20132066. https:\/\/doi.org\/10.1016\/S0140-6736(09)60492-X","journal-title":"Lancet"},{"issue":"5","key":"2522_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384\u2013386","journal-title":"Neurology"},{"key":"2522_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","volume":"24","author":"HE Moon","year":"2015","unstructured":"Moon HE, Paek SH (2015) Mitochondrial dysfunction in Parkinson\u2019s disease. Exp Neurobiol 24:103\u2013116. https:\/\/doi.org\/10.5607\/en.2015.24.2.103","journal-title":"Exp Neurobiol"},{"key":"2522_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.bbadis.2008.12.006","volume":"1792","author":"AHK Tsang","year":"2009","unstructured":"Tsang AHK, Chung KKK (2009) Oxidative and nitrosative stress in Parkinson\u2019s disease. Biochem Biophys Acta 1792:643\u2013650. https:\/\/doi.org\/10.1016\/j.bbadis.2008.12.006","journal-title":"Biochem Biophys Acta"},{"issue":"6","key":"2522_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S (2003) Parkinson\u2019s disease: mechanisms and models. Neuron 39(6):889\u2013909. https:\/\/doi.org\/10.1016\/S0896-6273(03)00568-3","journal-title":"Neuron"},{"key":"2522_CR6","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","volume":"47","author":"P Jenner","year":"1996","unstructured":"Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurol 47:S161\u2013S170","journal-title":"Neurol"},{"key":"2522_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","volume":"6","author":"JM Shulman","year":"2011","unstructured":"Shulman JM, De Jager PL, Feany MB (2011) Parkinson\u2019s disease: genetics and pathogenesis. Annu Rev Pathol 6:193\u2013222. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130242","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"2522_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368\u2013376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2522_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2217\/bmm.10.89","volume":"4","author":"M Frasier","year":"2010","unstructured":"Frasier M, Chowdhury S, Eberling J, Sherer T (2010) Biomarkers in Parkinson\u2019s disease: a funder\u2019s perspective. Biomark Med 4(5):723\u2013729. https:\/\/doi.org\/10.2217\/bmm.10.89","journal-title":"Biomark Med"},{"issue":"11","key":"2522_CR10","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","volume":"78","author":"BN Ames","year":"1981","unstructured":"Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858\u20136862","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2522_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.abb.2004.03.006","volume":"430","author":"KJ Yeum","year":"2004","unstructured":"Yeum KJ, Russell RM, Krinsky NI, Aldini G (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 430(1):97\u2013103. https:\/\/doi.org\/10.1016\/j.abb.2004.03.006","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"2522_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0361-9230(94)90285-2","volume":"33","author":"WH Church","year":"1994","unstructured":"Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson\u2019s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419\u2013425","journal-title":"Brain Res Bull"},{"issue":"5","key":"2522_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/oxfordjournals.aje.a008954","volume":"144","author":"JW Davis","year":"1996","unstructured":"Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson\u2019s disease. Am J Epidemiol 144(5):480\u2013484","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2522_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.20663","volume":"58","author":"LM Lau de","year":"2005","unstructured":"de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58(5):797\u2013800. https:\/\/doi.org\/10.1002\/ana.20663","journal-title":"Ann Neurol"},{"issue":"5","key":"2522_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/aje\/kwm127","volume":"166","author":"MG Weisskopf","year":"2007","unstructured":"Weisskopf MG, O\u2019Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson\u2019s disease. Am J Epidemiol 166(5):561\u2013567. https:\/\/doi.org\/10.1093\/aje\/kwm127","journal-title":"Am J Epidemiol"},{"issue":"17","key":"2522_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1212\/01.wnl.0000279518.10072.df","volume":"69","author":"A Alonso","year":"2007","unstructured":"Alonso A, Rodr\u00edguez LA, Logroscino G, Hern\u00e1n MA (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69(17):1696\u20131700. https:\/\/doi.org\/10.1212\/01.wnl.0000279518.10072.df","journal-title":"Neurology"},{"issue":"9","key":"2522_CR17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/aje\/kwp033","volume":"169","author":"H Chen","year":"2009","unstructured":"Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson\u2019s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169(9):1064\u20131069. https:\/\/doi.org\/10.1093\/aje\/kwp033","journal-title":"Am J Epidemiol"},{"issue":"8","key":"2522_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(14)70138-3","volume":"13","author":"MA Schwarzschild","year":"2014","unstructured":"Schwarzschild MA, Macklin EA, Ascherio A (2014) Parkinson Study Group SURE-PD Investigators: urate and neuroprotection trials. Lancet Neurol 13(8):758. https:\/\/doi.org\/10.1016\/S1474-4422(14)70138-3","journal-title":"Lancet Neurol"},{"issue":"11","key":"2522_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.24193","volume":"59","author":"M Vera De","year":"2008","unstructured":"De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H (2008) Gout and the risk of Parkinson\u2019s disease: a cohort study. Arthritis Rheum 59(11):1549\u20131554. https:\/\/doi.org\/10.1002\/art.24193","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2522_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/mds.21502","volume":"15","author":"T Annanmaki","year":"2007","unstructured":"Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson\u2019s disease. Mov Disord 15(8):1133\u20131137","journal-title":"Mov Disord"},{"issue":"5","key":"2522_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10072-015-2471-z","volume":"37","author":"E Vieru","year":"2016","unstructured":"Vieru E, K\u00f6ksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S (2016) The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson\u2019s disease. Neurol Sci 37(5):743\u2013747. https:\/\/doi.org\/10.1007\/s10072-015-2471-z","journal-title":"Neurol Sci"},{"issue":"9","key":"2522_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clineuro.2009.06.012","volume":"111","author":"E Andreadou","year":"2009","unstructured":"Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D (2009) Serum uric acid levels in patients with Parkinson\u2019s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111(9):724\u2013728. https:\/\/doi.org\/10.1016\/j.clineuro.2009.06.012","journal-title":"Clin Neurol Neurosurg"},{"key":"2522_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","volume":"211","author":"J Bov\u00e9","year":"2012","unstructured":"Bov\u00e9 J, Perier C (2012) Neurotoxin-based models of Parkinson\u2019s disease. Neuroscience 211:51\u201376. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.10.057","journal-title":"Neuroscience"},{"issue":"Suppl 2","key":"2522_CR24","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","volume":"14","author":"F Blandini","year":"2008","unstructured":"Blandini F, Armentero MT, Martignoni E (2008) The 6-ydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124\u2013S129. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.015","journal-title":"Parkinsonism Relat Disord"},{"key":"2522_CR25","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"2007","unstructured":"Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th\u00a0edn. Academic Press, San Diego","edition":"6"},{"key":"2522_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0169-328X(96)00018-6","volume":"39","author":"M Fujita","year":"1996","unstructured":"Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T (1996) Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Mol Brain Res 39:127\u2013136","journal-title":"Mol Brain Res"},{"key":"2522_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000358","author":"MR Sarookhani","year":"2017","unstructured":"Sarookhani MR, Haghdoost-Yazdi H, Sarbazi-Golezari A, Babayan-Tazehkand A, Rastgoo N (2017) Involvement of adenosine triphosphate -sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine- induced animal model of Parkinson\u2019s disease. Behav Pharmacol. https:\/\/doi.org\/10.1097\/FBP.0000000000000358","journal-title":"Behav Pharmacol"},{"key":"2522_CR28","doi-asserted-by":"crossref","unstructured":"Sarukhani M, Haghdoost-Yazdi H, Sarbazi A, Babayan-Tazehkand A, Dargahi T, Rastgoo N (2018) Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine- induced animal model of Parkinson\u2019s disease: behavioral, histological and biochemical studies. Neurol Res (unpublished data)","DOI":"10.1080\/01616412.2017.1390903"},{"issue":"6","key":"2522_CR29","doi-asserted-by":"publisher","first-page":"e100286","DOI":"10.1371\/journal.pone.0100286","volume":"9","author":"N Zhang","year":"2014","unstructured":"Zhang N, Shu HY, Huang T, Zhang QL, Li D, Zhang GQ, Peng XY, Liu CF, Luo WF, Hu LF (2014) Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE 9(6):e100286. https:\/\/doi.org\/10.1371\/journal.pone.0100286","journal-title":"PLoS ONE"},{"issue":"2","key":"2522_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neulet.2011.10.075","volume":"506","author":"TG Zhu","year":"2012","unstructured":"Zhu TG, Wang XX, Luo WF, Zhang QL, Huang TT, Xu XS, Liu CF (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506(2):175\u2013179. https:\/\/doi.org\/10.1016\/j.neulet.2011.10.075","journal-title":"Neurosci Lett"},{"issue":"5","key":"2522_CR31","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/jnc.12038","volume":"123","author":"L Gong","year":"2012","unstructured":"Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, Di PW, Huang T, Xu XS, Liu CF, Hu LF, Luo WF (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson\u2019s disease: linking to Akt\/GSK3\u03b2 signaling pathway. J Neurochem 123(5):876\u2013885. https:\/\/doi.org\/10.1111\/jnc.12038","journal-title":"J Neurochem"},{"issue":"3","key":"2522_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/jnc.12809","volume":"131","author":"MA Luca De","year":"2014","unstructured":"De Luca MA, Cauli O, Morelli M, Simola N (2014) Elevation of striatal urate in experimental models of Parkinson\u2019s disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? J Neurochem 131(3):284\u2013289. https:\/\/doi.org\/10.1111\/jnc.12809","journal-title":"J Neurochem"},{"issue":"9","key":"2522_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/mds.10486","volume":"18","author":"PS Fitzmaurice","year":"2003","unstructured":"Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson\u2019s disease. Mov Disord 18(9):969\u2013976. https:\/\/doi.org\/10.1002\/mds.10486","journal-title":"Mov Disord"},{"issue":"4","key":"2522_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","volume":"19","author":"GL Bowman","year":"2010","unstructured":"Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19(4):1331\u20131336. https:\/\/doi.org\/10.3233\/JAD-2010-1330","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"2522_CR35","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1460-9568.2005.04281.x","volume":"22","author":"PM Carvey","year":"2005","unstructured":"Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD (2005) 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22(5):1158\u20131168. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.04281.x","journal-title":"Eur J Neurosci"},{"issue":"1","key":"2522_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0304-3940(82)90004-0","volume":"30","author":"PH Cooper","year":"1982","unstructured":"Cooper PH, Novin D, Butcher LL (1982) Intracerebral 6-hydroxydopamine produces extensive damage to the blood-brain barrier in rats. Neurosci Lett 30(1):13\u201318","journal-title":"Neurosci Lett"},{"issue":"1","key":"2522_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13311-016-0497-4","volume":"14","author":"S Paganoni","year":"2017","unstructured":"Paganoni S, Schwarzschild MA (2017) Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics 14(1):148\u2013153. https:\/\/doi.org\/10.1007\/s13311-016-0497-4","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2522_CR38","doi-asserted-by":"publisher","first-page":"e0173731","DOI":"10.1371\/journal.pone.0173731","volume":"12","author":"M Wen","year":"2017","unstructured":"Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, Yu WF, Jiao L (2017) Serum uric acid levels in patients with Parkinson\u2019s disease: a meta-analysis. PLoS ONE 12(3):e0173731. https:\/\/doi.org\/10.1371\/journal.pone.0173731","journal-title":"PLoS ONE"},{"key":"2522_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","volume":"144","author":"H Yuan","year":"2005","unstructured":"Yuan H, Sarre S, Ebinge G, Michotte Y (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson\u2019s disease. J Neurosci Methods 144:35\u201345. https:\/\/doi.org\/10.1016\/j.jneumeth.2004.10.004","journal-title":"J Neurosci Methods"},{"key":"2522_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0306-4522(97)00498-3","volume":"84","author":"DN Abrous","year":"1998","unstructured":"Abrous DN, Rodriguez JJ, Montaron MF, Aurousseau C, Le Moal M, Barneoud P (1998). Behavioural recovery after unilateral lesion of the dopaminergic mesotelencephalic pathway: effect of repeated testing. Neurosci 84:213\u2013221","journal-title":"Neurosci"},{"key":"2522_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","volume":"162","author":"R Iancu","year":"2005","unstructured":"Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson\u2019s disease in mice. Behav Brain Res 162:1\u201310. https:\/\/doi.org\/10.1016\/j.bbr.2005.02.023","journal-title":"Behav Brain Res"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-018-2522-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-018-2522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-018-2522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T20:19:31Z","timestamp":1570997971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-018-2522-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1007\/s11064-018-2522-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"17 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}